Effect of integrated hepatitis C virus treatment on psychological distress in people with substance use disorders.

Autor: Aas CF; Department of Addiction Medicine, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway. christer.frode.aas@helse-bergen.no.; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. christer.frode.aas@helse-bergen.no.; Division of Psychiatry, Haukeland University Hospital, Bergen, Norway. christer.frode.aas@helse-bergen.no., Vold JH; Department of Addiction Medicine, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway.; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.; Division of Psychiatry, Haukeland University Hospital, Bergen, Norway., Chalabianloo F; Department of Addiction Medicine, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway.; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway., Løberg EM; Division of Psychiatry, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Psychology, University of Bergen, Bergen, Norway., Lim AG; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK., Vickerman P; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK., Johansson KA; Department of Addiction Medicine, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway.; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway., Fadnes LT; Department of Addiction Medicine, Haukeland University Hospital, Jonas Lies vei 65, 5021, Bergen, Norway.; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2024 Jan 08; Vol. 14 (1), pp. 816. Date of Electronic Publication: 2024 Jan 08.
DOI: 10.1038/s41598-024-51336-9
Abstrakt: People with substance use disorders (SUD) have a high prevalence of chronic hepatitis C virus (HCV) infection and mental health disorders. We aimed to assess the impact of integrated HCV treatment on psychological distress measured by Hopkins-symptom-checklist-10 (SCL-10). This multi-center randomized controlled trial evaluated psychological distress as a secondary outcome of integrated HCV treatment (INTRO-HCV trial). From 2017 to 2019, 289 participants were randomly assigned to receive either integrated or standard HCV treatment with direct-acting antiviral therapy. Integrated HCV treatment was delivered in eight decentralized outpatient opioid agonist therapy clinics and two community care centers; standard treatment was delivered in internal medicine outpatient clinics at centralized hospitals. Participants in the integrated treatment arm had a sustained virologic response of 93% compared to 73% for those in standard treatment arm. Psychological distress was assessed using SCL-10 prior to initiation of HCV treatment and 12 weeks after treatment completion. The mean SCL-10 score prior to HCV treatment was 2.2 (standard deviation [SD]: 0.7) for patients receiving integrated HCV treatment and 2.2 (SD: 0.8) for those receiving standard HCV treatment. Twelve weeks after the end of treatment, the mean SCL-10 score change was - 0.1 (- 0.3;0.0) in the integrated compared to the standard arm. Psychological distress did not substantially change during the treatment period and was not significantly different between the treatment arms.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje